ADC Therapeutics SA

NYSE:ADCT 株式レポート

時価総額：US$290.1m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

ADC Therapeutics マネジメント

マネジメント 基準チェック /34

ADC Therapeutics'の CEO はAmeet Mallikで、 May2022年に任命され、 の在任期間は 2.08年です。 の年間総報酬は$ 3.78Mで、 19.1%給与と80.9%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の1.21%を直接所有しており、その価値は$ 3.29M 。経営陣と取締役会の平均在任期間はそれぞれ1.8年と3.6年です。

主要情報

Ameet Mallik

最高経営責任者

US$3.8m

報酬総額

CEO給与比率19.1%
CEO在任期間2.3yrs
CEOの所有権1.0%
経営陣の平均在職期間2.1yrs
取締役会の平均在任期間3.8yrs

経営陣の近況

Recent updates

ADC Therapeutics SA (NYSE:ADCT) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Jul 18
ADC Therapeutics SA (NYSE:ADCT) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Limiting Concerns On ADC Therapeutics' Prospects

Jun 06

ADC Therapeutics SA's (NYSE:ADCT) 26% Dip In Price Shows Sentiment Is Matching Revenues

May 30
ADC Therapeutics SA's (NYSE:ADCT) 26% Dip In Price Shows Sentiment Is Matching Revenues

Analysts Are Updating Their ADC Therapeutics SA (NYSE:ADCT) Estimates After Its First-Quarter Results

May 10
Analysts Are Updating Their ADC Therapeutics SA (NYSE:ADCT) Estimates After Its First-Quarter Results

ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)

Mar 19

ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching Revenues

Mar 17
ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching Revenues

ADC Therapeutics SA (NYSE:ADCT) Shares Fly 38% But Investors Aren't Buying For Growth

Jan 18
ADC Therapeutics SA (NYSE:ADCT) Shares Fly 38% But Investors Aren't Buying For Growth

ADC Therapeutics: Rising From The Ashes Of A Halted Drug Trial

Dec 29

An Intrinsic Calculation For ADC Therapeutics SA (NYSE:ADCT) Suggests It's 38% Undervalued

Dec 14
An Intrinsic Calculation For ADC Therapeutics SA (NYSE:ADCT) Suggests It's 38% Undervalued

ADC Therapeutics: Navigating A Swirling Drain

Dec 01

ADC Therapeutics: Slowly Moving Toward Solvency

Aug 29

Are Investors Undervaluing ADC Therapeutics SA (NYSE:ADCT) By 32%?

Jul 11
Are Investors Undervaluing ADC Therapeutics SA (NYSE:ADCT) By 32%?

ADC Therapeutics: Maybe A 2024 Story

May 29

Analysts Have Just Cut Their ADC Therapeutics SA (NYSE:ADCT) Revenue Estimates By 28%

May 11
Analysts Have Just Cut Their ADC Therapeutics SA (NYSE:ADCT) Revenue Estimates By 28%

ADC Therapeutics SA's (NYSE:ADCT) Shares Lagging The Industry But So Is The Business

Apr 18
ADC Therapeutics SA's (NYSE:ADCT) Shares Lagging The Industry But So Is The Business

ADC Therapeutics stock slips after pricing stock offering by seller

Feb 02

Does ADC Therapeutics (NYSE:ADCT) Have A Healthy Balance Sheet?

Jan 16
Does ADC Therapeutics (NYSE:ADCT) Have A Healthy Balance Sheet?

Jose Carmona joins ADC Therapeutics as CFO

Dec 19

ADC Therapeutics Non-GAAP EPS of $0.13, revenue of $76.32M

Nov 08

ADC, Sobi Zynlonta for blood cancer subtype gets EMA panel backing for EU approval

Sep 16

ADC Therapeutics gets downgraded at Morgan Stanley, price target cut to $11

Sep 09

ADC Therapeutics Non-GAAP EPS of -$0.73, revenue of $17.29M misses by $13.93M

Aug 09

CEO報酬分析

ADC Therapeutics の収益と比較して、Ameet Mallik の報酬はどのように変化したか？
日付総報酬給与会社業績
Jun 30 2024n/an/a

-US$215m

Mar 31 2024n/an/a

-US$227m

Dec 31 2023US$4mUS$721k

-US$240m

Sep 30 2023n/an/a

-US$182m

Jun 30 2023n/an/a

-US$184m

Mar 31 2023n/an/a

-US$200m

Dec 31 2022US$11mUS$475k

-US$157m

報酬と市場: Ameetの 総報酬 ($USD 3.78M ) は、 US市場 ($USD 1.62M ) の同規模の企業の平均を上回っています。

報酬と収益: Ameetの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Ameet Mallik (51 yo)

2.3yrs

在職期間

US$3,779,425

報酬

Dr. Ameet Mallik M.B.A., M.S, is Director at ADC Therapeutics SA from June 30, 2022. He has been a Director of Atara Biotherapeutics, Inc. since August 2021. Dr. Mallik serves as Chief Executive Officer at...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Ameet Mallik
CEO & Director2.3yrsUS$3.78m1.03%
$ 3.0m
Jose Carmona
Chief Financial Officer1.8yrsUS$1.26m0.22%
$ 632.5k
Mohamed Zaki
Chief Medical Officer1.7yrsUS$4.40m0.24%
$ 700.0k
Lisa Kallebo
Corporate Controller & Chief Accounting Officerno dataデータなしデータなし
Michael Mulkerrin
Chief Technical Operations Officer2.7yrsデータなしデータなし
Patrick van Berkel
Chief Scientific Officer2.7yrsデータなしデータなし
Amanda Hamilton
Investor Relations Officerno dataデータなしデータなし
Peter Graham
Secretary & Chief Legal Officer1.8yrsデータなしデータなし
Eugenia Litz
Vice President of Investor Relations & Corporate Communicationsno dataデータなしデータなし
Kimberly Pope
Senior VP & Chief People Officer4.1yrsデータなしデータなし
Kristen Harrington-Smith
Chief Commercial Officer1.8yrsデータなしデータなし

2.1yrs

平均在職期間

56yo

平均年齢

経験豊富な経営陣: ADCTの経営陣は 経験豊富 であると考えられます ( 2年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Ameet Mallik
CEO & Director2.3yrsUS$3.78m1.03%
$ 3.0m
Michael Forer
Board Observer1.3yrsUS$846.56kデータなし
Peter Hug
Vice-Chairman & Lead Independent Director5.3yrsUS$212.61k0.15%
$ 427.9k
Ron Squarer
Chairman of the Board4.4yrsUS$526.73k1.6%
$ 4.6m
Jean-Pierre Bizzari
Independent Non-Executive Director2.3yrsUS$197.81k0.059%
$ 170.7k
Tyrell Rivers
Independent Non-Executive Director6.3yrsデータなしデータなし
Victor Sandor
Independent Non-Executive Director4.4yrsUS$227.72k0.074%
$ 216.0k
Robert Azelby
Independent Director1.3yrsUS$127.67k0.024%
$ 70.0k
Viviane Monges
Independent Non-Executive Director3.3yrsUS$231.33k0.098%
$ 284.3k
Thomas Pfisterer
Non-Independent Director7.9yrsUS$194.30k0.18%
$ 521.7k

3.8yrs

平均在職期間

57.5yo

平均年齢

経験豊富なボード: ADCTの 取締役会 は 経験豊富 であると考えられます ( 3.6年の平均在任期間)。